Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Oct;26(10):2341-57.
doi: 10.1002/jbmr.463.

Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness

Bruce W Hollis  1 , Donna Johnson, Thomas C Hulsey, Myla Ebeling, Carol L Wagner
Affiliations
Randomized Controlled Trial

Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness

Bruce W Hollis et al. J Bone Miner Res. 2011 Oct.

Erratum in

  • J Bone Miner Res. 2011 Dec; 26(12):3001

Abstract

The need, safety, and effectiveness of vitamin D supplementation during pregnancy remain controversial. In this randomized, controlled trial, women with a singleton pregnancy at 12 to 16 weeks' gestation received 400, 2000, or 4000 IU of vitamin D(3) per day until delivery. The primary outcome was maternal/neonatal circulating 25-hydroxyvitamin D [25(OH)D] concentration at delivery, with secondary outcomes of a 25(OH)D concentration of 80 nmol/L or greater achieved and the 25(OH)D concentration required to achieve maximal 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] production. Of the 494 women enrolled, 350 women continued until delivery: Mean 25(OH)D concentrations by group at delivery and 1 month before delivery were significantly different (p < 0.0001), and the percent who achieved sufficiency was significantly different by group, greatest in 4000-IU group (p < 0.0001). The relative risk (RR) for achieving a concentration of 80 nmol/L or greater within 1 month of delivery was significantly different between the 2000- and the 400-IU groups (RR = 1.52, 95% CI 1.24-1.86), the 4000- and the 400-IU groups (RR = 1.60, 95% CI 1.32-1.95) but not between the 4000- and. 2000-IU groups (RR = 1.06, 95% CI 0.93-1.19). Circulating 25(OH)D had a direct influence on circulating 1,25(OH)(2)D(3) concentrations throughout pregnancy (p < 0.0001), with maximal production of 1,25(OH)(2)D(3) in all strata in the 4000-IU group. There were no differences between groups on any safety measure. Not a single adverse event was attributed to vitamin D supplementation or circulating 25(OH)D levels. It is concluded that vitamin D supplementation of 4000 IU/d for pregnant women is safe and most effective in achieving sufficiency in all women and their neonates regardless of race, whereas the current estimated average requirement is comparatively ineffective at achieving adequate circulating 25(OH)D concentrations, especially in African Americans.

PubMed Disclaimer

Conflict of interest statement

All other authors (DDJ, TCH, ME, and CLW) state that they have no conflicts of interests.

Figures

Figure 1
Figure 1. Flow Diagram of Pregnancy Study
1IU denotes International Units
Figure 2
Figure 2. Circulating vitamin D3, its metabolites and intact parathyroid hormone as a function of vitamin D3 dose and time during pregnancy
Panels A, B, C and D show the mean (± S.E.M.) circulating concentrations of vitamin D3, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone at defined time points during pregnancy.
Figure 2
Figure 2. Circulating vitamin D3, its metabolites and intact parathyroid hormone as a function of vitamin D3 dose and time during pregnancy
Panels A, B, C and D show the mean (± S.E.M.) circulating concentrations of vitamin D3, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone at defined time points during pregnancy.
Figure 2
Figure 2. Circulating vitamin D3, its metabolites and intact parathyroid hormone as a function of vitamin D3 dose and time during pregnancy
Panels A, B, C and D show the mean (± S.E.M.) circulating concentrations of vitamin D3, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone at defined time points during pregnancy.
Figure 2
Figure 2. Circulating vitamin D3, its metabolites and intact parathyroid hormone as a function of vitamin D3 dose and time during pregnancy
Panels A, B, C and D show the mean (± S.E.M.) circulating concentrations of vitamin D3, 25(OH)D, 1,25(OH)2D and intact parathyroid hormone at defined time points during pregnancy.
Figure 3
Figure 3. Substrate-Product Relationships of Vitamin D Metabolites during Pregnancy
Panel A demonstrates the relationship between circulating vitamin D3 to control the production of 25(OH)D during pregnancy. Panel B demonstrates the relationship of circulating 25(OH)D to control the production of 1,25(OH)2D during pregnancy. All data points for all subjects in all groups were included in this analysis.
Figure 3
Figure 3. Substrate-Product Relationships of Vitamin D Metabolites during Pregnancy
Panel A demonstrates the relationship between circulating vitamin D3 to control the production of 25(OH)D during pregnancy. Panel B demonstrates the relationship of circulating 25(OH)D to control the production of 1,25(OH)2D during pregnancy. All data points for all subjects in all groups were included in this analysis.
Figure 4
Figure 4. Serum Calcium and Urinary Calcium/Creatinine Ratio as a Function of Vitamin D3 Dose and Time during Pregnancy
Panels A and B show the mean (± S.D.) serum calcium and urinary calcium/creatinine ratio at defined time points during pregnancy.
Figure 5
Figure 5. Relationship of Circulating 25(OH)D on the Urinary Calcium: Creatinine Ratio during Pregnancy
All data points are included for all study patients. Urinary calcium and urinary creatinine were measured in mmol/L. Ratio was calculated from measurement of urinary calcium (mmol/L) divided by measurement of urinary creatinine (mmol/L).
See this image and copyright information in PMC

Comment in

References

    1. Hatun S, Ozkan B, Orbak Z, Doneray H, Cizmecioglu F, Toprak D, Calikoglu AS. Vitamin D Deficiency in Early Infancy. J Nutr. 2005;135(2):279–282. - PubMed
    1. Ladhani S, Srinivasan L, Buchanan C, Allgrove J. Presentation of vitamin D deficiency. Arch Dis Child. 2004;89:781–784. - PMC - PubMed
    1. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122(5):1142–1152. - PubMed
    1. Yorifuji J, Yorifuji T, Tachibana K, Nagai S, Kawai M, Momoi T, Nagasaka H, Hatayama H, Nakahata T. Craniotabes in normal newborns: the earliest sign of subclinical vitamin D deficiency. J Clin Endocrinol Metab. 2008;93(5):1784–1788. - PubMed
    1. Anatoliotaki M, Tsilimigaki A, Tsekoura T, Schinaki A, Stefanaki S, Nicolaidou P. Congenital rickets due to maternal vitamin D deficiency in a sunny island of Greece. Acta Paediatr. 2003;92 (3):389–391. - PubMed

Publication types